QuickView for SLC29A2;jsessionid=1845A7328B4B6202092CA0352C204A27;jsessionid=30AB30F627DD7A6995D12AC272EB8A6B;jsessionid=3CA38BCDC8877D63022AC324B20AA9F5;jsessionid=D1C5D07BE8058216A031ADDD713C024B;jsessionid=F5A769C34B3BE4C90BFD7E72752D6547;jsessionid=F7559DBF6AF03705A190844602F27386;jsessionid=9AA1F07617DD4FC1A73256561E59DCBB;jsessionid=7B28B8846BBAFB22966901E7A331E1DE (gene)

1. Development of a Novel HEK293 Cell Model Lacking SLC29A1 to Study the Pharmacology of Endogenous SLC…
2. Amelioration of lipopolysaccharide-induced memory impairment in equilibrative nucleoside transporter…
3. The Critical Role of Equilibrative Nucleoside Transporter-2 in Modulating Cerebral Damage and Vascul…
4. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-tar…
5. Deletion of equilibrative nucleoside transporter-2 protects against lipopolysaccharide-induced neuro…

There were no clinical trials for SLC29A2;jsessionid=1845A7328B4B6202092CA0352C204A27;jsessionid=30AB30F627DD7A6995D12AC272EB8A6B;jsessionid=3CA38BCDC8877D63022AC324B20AA9F5;jsessionid=D1C5D07BE8058216A031ADDD713C024B;jsessionid=F5A769C34B3BE4C90BFD7E72752D6547;jsessionid=F7559DBF6AF03705A190844602F27386;jsessionid=9AA1F07617DD4FC1A73256561E59DCBB;jsessionid=7B28B8846BBAFB22966901E7A331E1DE